Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
14.53
+0.35 (2.47%)
Aug 13, 2025, 4:00 PM - Market closed
Simulations Plus Revenue
Simulations Plus had revenue of $20.36M in the quarter ending May 31, 2025, with 9.81% growth. This brings the company's revenue in the last twelve months to $80.38M, up 20.01% year-over-year. In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth.
Revenue (ttm)
$80.38M
Revenue Growth
+20.01%
P/S Ratio
3.63
Revenue / Employee
$325,437
Employees
247
Market Cap
292.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
| Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
| Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
| Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
| Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SLP News
- 1 day ago - SIMULATIONS PLUS STOCK: Lose Money on Your Simulations Plus, Inc. (NASDAQ:SLP) Investment? Contact BFA Law about its Securities Investigation - GlobeNewsWire
- 1 day ago - Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal – Hagens Berman - GlobeNewsWire
- 2 days ago - SLP BREAKING INVESTIGATION: BFA Law Announces an Investigation into Simulations Plus, Inc. after Stock Plummets over 25% on Impairment Charges – Contact BFA Law if You Lost Money - GlobeNewsWire
- 2 days ago - SLP BREAKING NEWS: Simulations Plus, Inc. Stock Significantly Declines After Impairment Charge and Auditor Departure -- Investors Urged to Contact BFA Law - Business Wire
- 6 days ago - Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal -- Hagens Berman - GlobeNewsWire
- 13 days ago - SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 16 days ago - Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design - Business Wire
- 4 weeks ago - Simulations Plus: Still Positioned For FDA In‑Silico Trend Despite Near‑Term Headwinds - Seeking Alpha